The Healthcare System Is Burning Down the Doctor-Patient Relationship

And physicians are being manipulated into helping build the machinery designed to replace them.

I LEFT TRADITIONAL HEALTHCARE

And there's no going back.

How Much Muscle Are GLP-1 Patients Actually Losing?

Two systematic reviews. One question. Different answers.

Before or After? The GLP-1 and Surgery Sequencing Question

The science of sequencing GLP-1 therapy and bariatric surgery — and why the answer is more complicated than anyone wants to admit.

Inside the Peptide Revolution — What the Science Actually Shows

The science underpinning the peptide revolution is genuinely extraordinary. The human trials are not. A physician goes deep on both.

Statins Don't Cause What You Think They Cause. Except When They Do.

Muscle damage. Memory loss. Cancer. Diabetes. Four fears, one physician, and what the evidence actually shows.

Statins Don't Lower LDL.Your Liver Does.

The receptor story that explains 40 years of cardiovascular outcomes data — and why the pleiotropic hypothesis was never the whole story.

The Longevity Stack

Six interventions. One thesis about time. What I take every morning and why the evidence earned each one a place in the rotation.

I'm 36. I'm a Physician. I Take a Statin Every Day.

Here's what the evidence actually says — and why I stopped waiting for symptoms before acting on it.

The Cholesterol Wars Are Over. LDL Won.

New guidelines. New trials. The same conclusion. The deniers didn't get the memo.

What Semaglutide Teaches Us About How GLP-1 Regulates Body Weight

It's not the injection site. It's not gut GLP-1. It's not thermogenesis. The pharmacokinetics of semaglutide across multiple trials offer a surprisingly clean window into how this molecule — and this biology — actually works.

Cleared for Takeoff

The Definitive GLP-1 Travel Guide — TSA, Storage, Dosing, and Everything In Between

SPECIAL EDITION: When the Drug Stops Working (Because You Stopped the Drug)

A new BMJ Medicine analysis quantifies what happens to cardiovascular risk after GLP-1 discontinuation. The numbers are striking. The framing some are applying to them is wrong.

The Drug That May Redefine What's Possible

Retatrutide may be the first pharmacotherapy to approach bariatric surgery–level weight loss. Phase 3 data now confirm what phase 2 only suggested: this is a categorically different molecule.

The Peptide Wild West (Part II)

The compounds with almost no human data — and one with an active safety signal. Plus the full scorecard and what to actually make of all this.

The Peptide Wild West (Part I)

RFK Jr. wants to unlock 14 banned compounds. Before you inject one, here's what the human evidence actually says.

SPECIAL EDITION: I've Been Taking Low-Dose Tirzepatide for Two Years. Here's What I've Learned.

A physician's honest account of off-label self-experimentation — and why I don't recommend you follow my lead.

Why Weight Returns After Stopping GLP-1 Therapy: The Biology You Need to Understand

Across randomized trials, stopping GLP-1/dual incretin therapy is typically followed by clinically meaningful weight regain and loss of cardiometabolic gains—often within months—highlighting obesity as a chronic, relapsing condition.

Why Obesity Is Not a Choice

The neuroscience and evolutionary biology behind a widely misunderstood disease

Obesity Care: Past, Present, and Future

How history can inform a more equitable future.

Beyond Blame: Reclaiming Nuance in Our Understanding of Obesity

Appetite, Food Noise, and What We've Been Getting Wrong

The GLP1 Problem